uniQure (NASDAQ:QURE) Stock Rating Upgraded by Wall Street Zen

uniQure (NASDAQ:QURE) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright reissued a “buy” rating on shares of uniQure in a research report on Tuesday, September 29th. Wolfe Research raised shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a report on Wednesday, July 29th. UBS Group began coverage on shares of uniQure in a report on Thursday, October 15th. They issued a “buy” rating and a $48.00 price target on the stock. Wells Fargo & Company reaffirmed an “overweight” rating and set a $75.00 price target on shares of uniQure in a research report on Tuesday, September 29th. Finally, Royal Bank Of Canada decreased their price objective on uniQure from $65.00 to $48.00 and set an “outperform” rating for the company in a report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $56.83.

uniQure Price Performance

Shares of QURE stock opened at $21.70 on Friday. uniQure has a 1-year low of $8.73 and a 1-year high of $51.72. The stock’s 50-day moving average is $31.86 and its 200 day moving average is $29.68. The company has a market cap of $1.52 billion, a P/E ratio of -6.18 and a beta of 1.14. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.52 and a quick ratio of 11.52.

uniQure (NASDAQ:QURE) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. The company had revenue of $5.20 million for the quarter, compared to analyst estimates of $6.17 million. uniQure had a negative return on equity of 96.34% and a negative net margin of 1,154.84%. Research analysts predict that uniQure will post -3.84 earnings per share for the current fiscal year.

Institutional Trading of uniQure

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Privium Fund Management B.V. acquired a new stake in uniQure during the third quarter valued at $5,223,000. Pekin Hardy Strauss Inc. increased its holdings in uniQure by 63.3% in the third quarter. Pekin Hardy Strauss Inc. now owns 153,890 shares of the biotechnology company’s stock valued at $3,718,000 after buying an additional 59,640 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in uniQure in the third quarter valued at $86,000. China Universal Asset Management Co. Ltd. purchased a new position in uniQure in the third quarter valued at $310,000. Finally, Maxi Investments CY Ltd acquired a new position in shares of uniQure in the third quarter worth about $966,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands.

Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.